文献速递细胞病理与分子病理泌尿与男性生殖病理

人工智能增强数字尿液细胞学用于膀胱癌诊断评估

Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis.
PubMed 文献 · Cancer Cytopathol · 2024-07-14

本研究评估AIxURO平台辅助尿液细胞学诊断膀胱癌的效果,1名细胞病理医师和2名细胞技术员回顾116例尿液细胞学玻片及全切片图像,比较显微镜、全切片图像审阅和AIxURO三种方式。AIxURO提高了非典型尿路上皮细胞(AUC)和可疑高级别尿路上皮癌(SHGUC)病例的敏感性、阳性预测值和阴性预测值,并显著缩短筛查时间。

要点

  • AIxURO提高AUC病例敏感性至63.9%,SHGUC病例敏感性至33.3%。
  • AIxURO将筛查时间较显微镜缩短52.3%-83.2%,较全切片图像审阅缩短43.6%-86.7%。
  • 观察者间一致性中等(κ=0.57-0.61),细胞病理医师自身一致性较高(κ=0.75-0.88)。

核心结论

  • AIxURO在尿液细胞学诊断中可提高敏感性和效率,整合至筛查流程可显著缩短筛查时间。

研究设计与样本

  • 回顾性评估AIxURO平台,1名细胞病理医师和2名细胞技术员审阅116例尿液细胞学玻片及全切片图像,采用三种诊断方式。

主要发现

  • AUC病例:AIxURO将敏感性从25.0%-30.6%提高至63.9%,PPV从21.6%-24.3%提高至31.1%,NPV从91.3%-91.6%提高至95.3%。
  • SHGUC病例:AIxURO将敏感性从15.2%-27.3%提高至33.3%,PPV从31.3%-47.4%提高至61.1%,NPV从91.6%-92.7%提高至93.3%。
  • 二分类诊断:AIxURO将敏感性从77.8%-82.2%提高至90.0%,NPV从91.7%-93.4%提高至95.8%。
  • 观察者间一致性:所有方法κ=0.57-0.61;细胞病理医师自身一致性κ=0.75-0.88,高于细胞技术员。
  • 筛查时间:AIxURO较显微镜缩短52.3%-83.2%,较全切片图像审阅缩短43.6%-86.7%;筛查阳性(AUC+)病例耗时多于阴性病例。

关键数值与推荐

  • 采用巴黎系统尿液细胞学报告标准(TPS)进行TPS引导诊断和二分类诊断。

临床怎么用

  • AIxURO可辅助尿液细胞学筛查,提高AUC和SHGUC病例的敏感性并缩短筛查时间。
  • 整合AIxURO至细胞病理筛查流程可能改善整体诊断流程效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the diagnostic effectiveness of the AIxURO platform, an artificial intelligence-based tool, to support urine cytology for bladder cancer management, which typically requires experienced cytopathologists and substantial diagnosis time. METHODS: One cytopathologist and two cytotechnologists reviewed 116 urine cytology slides and corresponding whole-slide images (WSIs) from urology patients. They used three diagnostic modalities: microscopy, WSI review, and AIxURO, per The Paris System for Reporting Urinary Cytology (TPS) criteria. Performance metrics, including TPS-guided and binary diagnosis, inter- and intraobserver agreement, and screening time, were compared across all methods and reviewers. RESULTS: AIxURO improved diagnostic accuracy by increasing sensitivity (from 25.0%-30.6% to 63.9%), positive predictive value (PPV; from 21.6%-24.3% to 31.1%), and negative predictive value (NPV; from 91.3%-91.6% to 95.3%) for atypical urothelial cell (AUC) cases. For suspicious for high-grade urothelial carcinoma (SHGUC) cases, it improved sensitivity (from 15.2%-27.3% to 33.3%), PPV (from 31.3%-47.4% to 61.1%), and NPV (from 91.6%-92.7% to 93.3%). Binary diagnoses exhibited an improvement in sensitivity (from 77.8%-82.2% to 90.0%) and NPV (from 91.7%-93.4% to 95.8%). Interobserver agreement across all methods showed moderate consistency (κ = 0.57-0.61), with the cytopathologist demonstrating higher intraobserver agreement than the two cytotechnologists across the methods (κ = 0.75-0.88). AIxURO significantly reduced screening time by 52.3%-83.2% from microscopy and 43.6%-86.7% from WSI review across all reviewers. Screening-positive (AUC+) cases required more time than negative cases across all methods and reviewers. CONCLUSIONS: AIxURO demonstrates the potential to improve both sensitivity and efficiency in bladder cancer diagnostics via urine cytology. Its integration into the cytopathological screening workflow could markedly decrease screening times, which would improve overall diagnostic processes.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Liu TJ, Yang WC, Huang SM, et al. Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis. Cancer Cytopathol. 2024. PMID: 39003588. doi:10.1002/cncy.22884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。